Ablexis

Ablexis is a private, platform-focused biotech company that has created and licenses the AlivaMab Mouse, a superior transgenic mouse designed for therapeutic antibody discovery. Its technology is validated and used by a majority of the world's top pharmaceutical companies at over a dozen sites globally. The company generates revenue through licensing agreements and maintains a strategic relationship with AlivaMab Biologics, a separate service entity that offers antibody discovery outsourcing. Ablexis's core value proposition lies in its engineered platform, which aims to produce antibodies with high potency, specificity, and developability.

AlivaMab Mouse: A next-generation transgenic mouse platform with synthetic, autonomously functioning human immunoglobulin transgenes. It features a curated repertoire of human V genes and unique human/mouse genetic elements designed to generate high-quality, fully human antibodies with improved developability profiles.

Ablexis competes in the transgenic antibody discovery platform space against companies like Harbour BioMed (H2L2 mouse), Trianni, Inc., and legacy platforms like the VelocImmune mouse (Regeneron). It also faces broader competition from in vitro display technologies (phage, yeast, mammalian) and emerging AI/ computational discovery platforms. Its key competitive advantage is its validated adoption by major pharma and its design for antibody developability.